Quest and Waters Turn At-Home HPV Into a Routed Care Program
Quest and Waters are building a clinician-ordered at-home HPV program that pairs self-collection with centralized lab processing and routed follow-up.
What is this trend?
Quest and Waters are turning at-home HPV screening into a clinician-ordered, routed care workflow that links self-collection, centralized lab processing, and follow-up through provider and payer channels.
- At-home HPV is shifting from convenience to a managed care pathway.
- Clinician ordering and closed-loop routing are now part of the product.
- Quest will process mailed or drop-off samples on its automated BD COR system.
- Distribution will run through providers, consumer channels, and payer gap-in-care programs.
- Coverage may broaden across commercial, Medicaid, and Medicare plans.
What’s the latest?
Quest and Waters said on Oct.
How it developed
- Decentralized diagnostics become workflow platforms, blood screening enters clinical care, and liquid biopsy turns decision support
- Regulated Decentralized Diagnostics Are Becoming Workflow Platforms
- Companion diagnostics become commercial platforms, FDA makes AI validation the moat, and pathology consolidates
- Decentralized Testing Expansion
- ctDNA Gates Therapy, AI Moves Into Workflow, and Distribution Becomes the New Moat
- Decentralized Testing Expansion
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
If you operate in this industry
If you sell into this industry
Clinical Data Teams Shift Focus to AI Validation and Human Oversight
News analysis on CDMI 2026: clinical data teams emphasize AI validation, human oversight, and regulated change control.
The Clinical Trial Vanguard · News
Read →Generative AI Is Coming to Medical Devices. FDA Is Already Thinking About What Comes Next.
News analysis on FDA’s discussion paper for regulating generative AI medical devices as workflow platforms.
The National Law Review · News
Read →When the Medical IoT Starts Generating Answers, What Exactly Is the Regulated Device?
News analysis on FDA-regulated GenAI medical IoT device systems and testing/versioning as workflow platforms.
IoT Business News · News
Read →If you invest in this industry
Q&A: Teal Health scores $22M to broaden at-home cervical cancer screening
Interview with Kara Egan on Teal Health’s $22M push to scale at-home HPV screening via telehealth workflows.
MobiHealthNews · News
Read →Will Labcorp’s (LH) Digital Trial Upgrades and New Diagnostics Deal Subtly Shift Its Growth Narrative? - Simply Wall St News
News analysis on Labcorp’s digital trial upgrades and new tests, showing diagnostics moving into workflow platforms.
Simply Wall Street · News
Read →Does Blood Testing Alliance Change The Bull Case For Siemens Healthineers Stock?
Analysis of Siemens Healthineers’ blood-testing and oncology launches, assessing regulated diagnostics as workflow platforms.
Simply Wall Street · News
Read →